Literature DB >> 26714710

Methods for the Analyses of Inhibitor-Induced Aberrant Multimerization of HIV-1 Integrase.

Jacques J Kessl1, Amit Sharma2,3, Mamuka Kvaratskhelia2.   

Abstract

HIV-1 integrase (IN) is an important therapeutic target as its function is essential for the viral lifecycle. The discovery of multifunctional allosteric IN inhibitors or ALLINIs, which potently impair viral replication by promoting aberrant, higher order IN multimerization as well as inhibit IN interactions with its cellular cofactor, LEDGF/p75, has opened new venues to exploit IN multimerization as a therapeutic target. Furthermore, the recent discovery of multimerization selective IN inhibitors or MINIs, has provided new investigational probes to study the direct effects of aberrant IN multimerization in vitro and in infected cells. Here we describe three complementary methods designed to detect and quantify the effects of these new classes of inhibitors on IN multimerization. These methods include a homogenous time-resolved fluorescence-based assay which allows for measuring EC50 values for the inhibitor-induced aberrant IN multimerization, a dynamic light scattering-based assay which allows for monitoring the formation and sizes of oligomeric IN particles in a time-dependent manner, and a chemical cross-linking-based assay of interacting IN subunits which allows for the determination of IN oligomers in viral particles.

Entities:  

Keywords:  Chemical cross-linking; Dynamic light scattering; HIV-1 integrase; Homogenous time-resolved fluorescence; Protein multimerization

Mesh:

Substances:

Year:  2016        PMID: 26714710      PMCID: PMC4793731          DOI: 10.1007/978-1-4939-3046-3_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  31 in total

1.  Retroviral DNA integration: reaction pathway and critical intermediates.

Authors:  Min Li; Michiyo Mizuuchi; Terrence R Burke; Robert Craigie
Journal:  EMBO J       Date:  2006-02-16       Impact factor: 11.598

2.  The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.

Authors:  Lei Feng; Amit Sharma; Alison Slaughter; Nivedita Jena; Yasuhiro Koh; Nikolozi Shkriabai; Ross C Larue; Pratiq A Patel; Hiroaki Mitsuya; Jacques J Kessl; Alan Engelman; James R Fuchs; Mamuka Kvaratskhelia
Journal:  J Biol Chem       Date:  2013-04-24       Impact factor: 5.157

3.  Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Authors:  Lee D Fader; Eric Malenfant; Mathieu Parisien; Rebekah Carson; François Bilodeau; Serge Landry; Marc Pesant; Christian Brochu; Sébastien Morin; Catherine Chabot; Ted Halmos; Yves Bousquet; Murray D Bailey; Stephen H Kawai; René Coulombe; Steven LaPlante; Araz Jakalian; Punit K Bhardwaj; Dominik Wernic; Patricia Schroeder; Ma'an Amad; Paul Edwards; Michel Garneau; Jianmin Duan; Michael Cordingley; Richard Bethell; Stephen W Mason; Michael Bös; Pierre Bonneau; Marc-André Poupart; Anne-Marie Faucher; Bruno Simoneau; Craig Fenwick; Christiane Yoakim; Youla Tsantrizos
Journal:  ACS Med Chem Lett       Date:  2014-01-22       Impact factor: 4.345

4.  Nucleoprotein intermediates in HIV-1 DNA integration visualized by atomic force microscopy.

Authors:  Svetlana Kotova; Min Li; Emilios K Dimitriadis; Robert Craigie
Journal:  J Mol Biol       Date:  2010-04-21       Impact factor: 5.469

5.  The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding.

Authors:  Katrien Busschots; Jo Vercammen; Stéphane Emiliani; Richard Benarous; Yves Engelborghs; Frauke Christ; Zeger Debyser
Journal:  J Biol Chem       Date:  2005-03-04       Impact factor: 5.157

6.  Evolution of raltegravir resistance during therapy.

Authors:  Nadine Sichtig; Saleta Sierra; Rolf Kaiser; Martin Däumer; Stefan Reuter; Eugen Schülter; Andre Altmann; Gerd Fätkenheuer; Ulf Dittmer; Herbert Pfister; Stefan Esser
Journal:  J Antimicrob Chemother       Date:  2009-05-14       Impact factor: 5.790

7.  Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.

Authors:  Nick Shkriabai; Sachindra S Patil; Sonja Hess; Scott R Budihas; Robert Craigie; Terrence R Burke; Stuart F J Le Grice; Mamuka Kvaratskhelia
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

8.  LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration.

Authors:  Ming-Chieh Shun; Nidhanapati K Raghavendra; Nick Vandegraaff; Janet E Daigle; Siobhan Hughes; Paul Kellam; Peter Cherepanov; Alan Engelman
Journal:  Genes Dev       Date:  2007-07-15       Impact factor: 11.361

9.  The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.

Authors:  Melissa Wares; Thibault Mesplède; Peter K Quashie; Nathan Osman; Yingshan Han; Mark A Wainberg
Journal:  Retrovirology       Date:  2014-01-17       Impact factor: 4.602

10.  Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.

Authors:  Erwann Le Rouzic; Damien Bonnard; Sophie Chasset; Jean-Michel Bruneau; Francis Chevreuil; Frédéric Le Strat; Juliette Nguyen; Roxane Beauvoir; Céline Amadori; Julie Brias; Sophie Vomscheid; Sylvia Eiler; Nicolas Lévy; Olivier Delelis; Eric Deprez; Ali Saïb; Alessia Zamborlini; Stéphane Emiliani; Marc Ruff; Benoit Ledoussal; François Moreau; Richard Benarous
Journal:  Retrovirology       Date:  2013-11-21       Impact factor: 4.602

View more
  5 in total

1.  A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain.

Authors:  Disha Patel; Janet Antwi; Pratibha C Koneru; Erik Serrao; Stefano Forli; Jacques J Kessl; Lei Feng; Nanjie Deng; Ronald M Levy; James R Fuchs; Arthur J Olson; Alan N Engelman; Joseph D Bauman; Mamuka Kvaratskhelia; Eddy Arnold
Journal:  J Biol Chem       Date:  2016-09-19       Impact factor: 5.157

2.  Identification and Optimization of a Novel HIV-1 Integrase Inhibitor.

Authors:  Daniel Adu-Ampratwum; Yuhan Pan; Pratibha C Koneru; Janet Antwi; Ashley C Hoyte; Jacques Kessl; Patrick R Griffin; Mamuka Kvaratskhelia; James R Fuchs; Ross C Larue
Journal:  ACS Omega       Date:  2022-01-24

3.  Multi-Substituted Quinolines as HIV-1 Integrase Allosteric Inhibitors.

Authors:  Long Phi Dinh; Jian Sun; Courtney D Glenn; Krunal Patel; Julie A Pigza; Matthew G Donahue; Larry Yet; Jacques J Kessl
Journal:  Viruses       Date:  2022-07-02       Impact factor: 5.818

4.  Synthesis and Evaluation of Aryl Quinolines as HIV-1 Integrase Multimerization Inhibitors.

Authors:  Nicholas G Jentsch; Alison P Hart; Jared D Hume; Jian Sun; Kaitlin A McNeely; Chiyang Lama; Julie A Pigza; Matthew G Donahue; Jacques J Kessl
Journal:  ACS Med Chem Lett       Date:  2018-09-14       Impact factor: 4.632

5.  Quinolines from the cyclocondensation of isatoic anhydride with ethyl acetoacetate: preparation of ethyl 4-hydroxy-2-methylquinoline-3-carboxylate and derivatives.

Authors:  Nicholas G Jentsch; Jared D Hume; Emily B Crull; Samer M Beauti; Amy H Pham; Julie A Pigza; Jacques J Kessl; Matthew G Donahue
Journal:  Beilstein J Org Chem       Date:  2018-09-28       Impact factor: 2.544

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.